TNF and rheumatoid arthritis: Current treatment focuses on targetingthe inflammatory responses such as inhibiting the interleukin (IL)-1and tumor necrosis factor-alpha (TNF-α).386,387 Various chemoattractant are known to promote neutrophil migrationinto the joints during RA.388 Microvesiclesproduced by neutrophils can readily enter cartilage and protect joints.389 Therefore, neutrophil membrane-coated PLGAnanoparticles were designed.66 These mimicsneutralized pro-inflammatory cytokines (IL-1β and TNF-α),suppressed synovial inflammation, targeted cartilage matrix, and protectedchondrocytes against damage.